Rod Lippincott Sells 5,000 Shares of Heska Corp. (HSKA) Stock
Heska Corp. (NASDAQ:HSKA) EVP Rod Lippincott sold 5,000 shares of the stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $64.85, for a total value of $324,250.00. Following the completion of the transaction, the executive vice president now owns 10,192 shares in the company, valued at $660,951.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Heska Corp. (NASDAQ:HSKA) opened at 66.48 on Friday. The firm has a market cap of $458.58 million, a P/E ratio of 53.23 and a beta of 0.74. Heska Corp. has a 1-year low of $26.25 and a 1-year high of $69.80. The stock has a 50 day moving average price of $57.42 and a 200-day moving average price of $47.91.
Heska Corp. (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 1st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.20. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. The firm had revenue of $33.40 million for the quarter, compared to analyst estimates of $31.36 million. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. Equities research analysts forecast that Heska Corp. will post $1.32 EPS for the current year.
Large investors have recently bought and sold shares of the company. MSI Financial Services Inc acquired a new stake in Heska Corp. during the third quarter worth $103,000. Bank of Montreal Can acquired a new stake in Heska Corp. during the second quarter worth $128,000. Acrospire Investment Management LLC raised its stake in Heska Corp. by 786.3% in the second quarter. Acrospire Investment Management LLC now owns 4,396 shares of the company’s stock worth $163,000 after buying an additional 3,900 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in Heska Corp. by 7.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,853 shares of the company’s stock worth $180,000 after buying an additional 320 shares in the last quarter. Finally, BlackRock Inc. raised its stake in Heska Corp. by 863.1% in the second quarter. BlackRock Inc. now owns 5,095 shares of the company’s stock worth $189,000 after buying an additional 4,566 shares in the last quarter. Institutional investors own 71.80% of the company’s stock.
A number of research analysts have commented on HSKA shares. B. Riley reiterated a “buy” rating and issued a $42.50 price objective on shares of Heska Corp. in a research report on Monday, August 1st. Sidoti lowered Heska Corp. from a “buy” rating to a “neutral” rating in a research report on Tuesday. Zacks Investment Research lowered Heska Corp. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 5th. Finally, Gabelli lowered Heska Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $55.83.
ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2016/11/25/rod-lippincott-sells-5000-shares-of-heska-corp-hska-stock.html.
About Heska Corp.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Stock Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related stocks with our FREE daily email newsletter.